Voyager Therapeutics, Inc. (FRA:VT6)
3.140
-0.078 (-2.42%)
Last updated: Jan 28, 2026, 8:07 AM CET
Voyager Therapeutics Revenue
Voyager Therapeutics had revenue of $13.37M USD in the quarter ending September 30, 2025, a decrease of -45.73%. This brings the company's revenue in the last twelve months to $31.32M, down -80.88% year-over-year. In the year 2024, Voyager Therapeutics had annual revenue of $80.00M, down -68.00%.
Revenue (ttm)
$31.32M
Revenue Growth
-80.88%
P/S Ratio
6.84
Revenue / Employee
$182.07K
Employees
172
Market Cap
182.51M EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 80.00M | -170.01M | -68.00% |
| Dec 31, 2023 | 250.01M | 209.10M | 511.16% |
| Dec 31, 2022 | 40.91M | 3.49M | 9.33% |
| Dec 31, 2021 | 37.42M | -133.71M | -78.14% |
| Dec 31, 2020 | 171.13M | 66.74M | 63.93% |
| Dec 31, 2019 | 104.39M | 96.77M | 1,270.14% |
| Dec 31, 2018 | 7.62M | -2.52M | -24.82% |
| Dec 31, 2017 | 10.14M | -4.09M | -28.73% |
| Dec 31, 2016 | 14.22M | -3.11M | -17.96% |
| Dec 31, 2015 | 17.33M | - | - |
| Dec 31, 2014 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Allane SE | 827.69M |
| ADM Hamburg Aktiengesellschaft | 389.86M |
| centrotherm international AG | 288.81M |
| Eleving Group | 203.19M |
| ÜSTRA Hannoversche Verkehrsbetriebe Aktiengesellschaft | 171.37M |
| LEWAG Holding Aktiengesellschaft | 112.27M |
| Deutsche Real Estate AG | 33.64M |
| STINAG Stuttgart Invest AG | 28.92M |
Voyager Therapeutics News
- 2 months ago - Voyager Therapeutics (VYGR) Reports Q3 Loss, Tops Revenue Estimates - Nasdaq
- 2 months ago - Voyager Therapeutics (VYGR) Partners with Transition Bio for ALS and FTD Drug Discovery - GuruFocus
- 2 months ago - Voyager Therapeutics GAAP EPS of -$0.47 beats by $0.05, revenue of $13.37M beats by $5.51M - Seeking Alpha
- 2 months ago - Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia - GlobeNewsWire
- 2 months ago - Voyager Reports Third Quarter 2025 Financial and Operating Results - GlobeNewsWire
- 5 months ago - Voyager Therapeutics, Inc. (VYGR) Presents At Citi's Biopharma Back To School Conference Transcript - Seeking Alpha
- 5 months ago - Voyager to Present at Upcoming Investor Conferences - GlobeNewsWire
- 6 months ago - Voyager Reports Second Quarter 2025 Financial and Operating Results - GlobeNewsWire